Fluent

Fluent Capital Expenditures

Delisted

The Capital Expenditures (CapEx) of Fluent (TIUM.U.CN) as of Nov 5, 2026 is -6.34 M USD. In the previous year, Capital Expenditures (CapEx) was -6.80 M USD — a change of -6.78% (higher).

Capital Expenditures

-6.34 MUSD

YoY

-6.78%

Last updated:

Capital Expenditures (CapEx) of Fluent is 2023 -6.34 M USD. Capital Expenditures (CapEx) of Fluent was 2022 -6.80 M USD. It decreases by -6.78% higher compared to the previous year.

The Fluent Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-14.16 M USD
Jan 1, 2020
-5.19 M USD
Jan 1, 2021
-21.38 M USD
Jan 1, 2022
-6.80 M USD
Jan 1, 2023
-6.34 M USD
The Fluent Capital Expenditures history
YEARCapital ExpendituresYoY
-6.34 MUSD-6.78%
-6.80 MUSD-68.20%
-21.38 MUSD+311.77%
-5.19 MUSD-63.34%
-14.16 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluent Stock analysis

What does Fluent do? Fluent Corp operates under the private label Fluent, selling medical cannabis products in Florida, Texas, and Pennsylvania. The company's products include oral drops, capsules, suppositories, topicals, syringes, dried flower, pre-rolls, cartridges, edibles, and accessories. Subsidiaries such as Cansortium Holdings LLC and Cansortium Florida, LLC handle production and sales, while Fluent Servicing, LLC manages servicing aspects. The company's revenue comes from direct sales of medical cannabis products through its licensed operations in multiple states. Fluent Corp's target customers are patients seeking medical cannabis treatments, with products tailored to various consumption methods. The company leverages its subsidiaries to maintain compliance and expand its market reach across different states. Sales are conducted through licensed dispensaries and medical cannabis programs, focusing on the healthcare segment of the cannabis industry. The business model relies on the production and sale of medical cannabis under the private label Fluent, utilizing subsidiaries to manage state-specific operations. Products are distributed through established medical cannabis channels, with no mention of additional revenue streams beyond product sales. The company's focus remains on the medical cannabis market, serving patients in Florida, Texas, and Pennsylvania. Fluent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluent stock

Capital Expenditures (CapEx) of Fluent is -6.34 M USD in 2023.

Capital Expenditures (CapEx) of Fluent changed from -6.80 M USD to -6.34 M USD, representing a -6.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Fluent since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Fluent historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluent

All Key Metrics — Fluent